35 th Annual J.P. Morgan Healthcare Conference January 2017 FLRY3

Transcription

1 35 th Annual J.P. Morgan Healthcare Conference January 2017 FLRY3 For more information, please contact the IR team:

2 Our history makes us one of the greatest and most respected healthcare companies in Brazil Since 1926 providing complete diagnostic medicine portfolio: R$ 2.2 bn of gross revenue, 3.5 thousand of types of exams in 37 different areas: Clinical Analyses (Routine, pathology and high complexity exams): 55 MM exams and R$ 1.3 bn of gross revenue. Imaging and others: 4 MM exams and R$ 936 MM of gross revenue. 8.3 thousand employees and 1.8 thousand physicians providing services. Service Center (84% of revenues) Operations in Hospitals (14% of revenues) Reference laboratory (~1% of revenues) Business lines 138 Patient Service Centers (PSCs) with more than 100 thousand m². Clinical Analysis in 22 hospital institutions. Medium and high complexity exams to other laboratories and hospitals. Figures in LTM otherwise as indicated. 2

3 The Company s markets gathers 69% of the beneficiaries of private medicine Current cities Adjacencies 36% beneficiaries 33% beneficiaries 26 cities Average of 1.4M inhabitant/city 19% of country population 40% of country population for income classes A and B 2.2 thousand cities Average of 33 thousand inhabitant/city 36% of country population 31% of country population for income classes A and B New markets 32% beneficiaries 3.3 thousand cities Average of 28 thousand inhabitant/city 46% of country population 29% of country population for income classes A and B

4 Recognized brands, with focus on the premium and upper-intermediate segments high growth and margin segments São Paulo (41 PSCs) Rio de Janeiro (42 PSCs) South (31 PSCs) Northeast (23 PSCs) Federal District (01 PSC) Premium (23) (07) (22) (01) Intermediate (18) (35) (09) (23) Basic Premium brands, top of mind, in São Paulo, Rio de Janeiro, Rio Grande do Sul and Brasilia. National brand (a+), launched in Strong potential for capturing intermediary segment. 4

5 Financial and customer s satisfaction indicators has shown sustainable growth EBITDA¹ (R$ MM) and margin (%) Operating Cash Flow (R$ MM) and Operating Cash Flow / EBITDA LTM (%) 17.7% % % % % % % % CAGR +32.8% % 75% % % ROIC LTM Net Promoter Score NPS ³ 2016 LTM 26.0% 23.4% 14.1% 16.0% 20.8% 31.9% 64.1% 64.6% 66.1% 69.3% 73.0% LTM 3T15 4T15 1T16 2T16 3T16 ¹ EBITDA ajusted in 2015 and 2014 excluding non recurring. 2 ROIC adjusted without goodwill. ³ NPS measures the level of recommendation to family and friends after the use of our services. The methodology was updated in

6 Grupo Fleury is present in the most important market places and Grupo Fleury s Market share Attendence (%)¹: São Paulo Metropolitan Region market share: Other Metropolitan Regions market share: Rio de Janeiro 9% 10% Premium 40.6% in premium segment 15.8% 30% 27% Upper Intermediate SP 8.8% in upper intermediate segment Rio Grande do Sul 18.5% 24% Intermediate Paraná 5.9% 36% Basic Bahia 10.5% Fleury brand focus A+SP brand focus Pernambuco 9.1% ¹Source: Grupo Fleury s estimates, based on ANS. 6

7 Grupo Fleury Expansion Plan (Next 5 years ) Number of New Patient Service Centers (PSCs) Fleury brand a+ SP brand Rio de Janeiro brands South brands 18 to 22 PSCs 21 to 28 PSCs 21 to 25 PSCs 13 to 15 PSCs Total of 73 to 90 PSCs B2B: Growth in line with PSCs though evolution in existing operations and adding of new contracts keeping its representivity in the Company s revenue 7

8 Our identity pillars make us unique Competency map Competitive positioning Customer service excellence Medicine and Health expertise Presence in major economic centers Best solution to customers and physicians. Intensification and deepening of the relationship with customers and physicians. Focus on the needs and resolution of customer and physicians problems. Unquestionable quality and offering of innovative products and services. Extensive performance in the healthcare value chain Innovation, research and development This allows us to create a close relationship with our clients and provide conclusive diagnostics to the physicians.